Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (4198)	5/4/1998 4:47:00 PM
From: Andreas Helke	Read Replies (1) of 6136

It is nice that the most advanced Agouron cancer drug is an anti angiogenesis drug and I am beginning to get cautious about cancer biotechs that don't have an anti angiogenesis drug in their pipeline. But there is a big difference between the average anti angiogenesis drug which is more or less effective against cancer and endostatin in mice which shrinks tumors to insignificance and seems to keeps all of the treated mice alive indefinitely. (T. Boehm et. al. - Nature, vol 390, 27. november 1997, pages 404-407) Andreas

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next